eIF3β Inhibitors

The class of compounds known as eIF3β inhibitors represents a group of small molecules that specifically target and disrupt the function of the eukaryotic translation initiation factor 3 subunit β (eIF3β). eIF3β is a crucial component of the eIF3 complex, which plays a pivotal role in regulating the initiation of protein synthesis. These inhibitors have gained significant attention in molecular research due to their ability to modulate cellular processes at the level of translation initiation. By interfering with the activity of eIF3β, these compounds exert a downstream effect on protein synthesis, thereby influencing various cellular functions. The mechanism of action of eIF3β inhibitors primarily revolves around their ability to hinder the assembly and function of the eIF3 complex. The eIF3 complex plays a pivotal role in orchestrating the assembly of ribosomes on messenger RNAs (mRNAs) during translation initiation.

eIF3β inhibitors disrupt this process by targeting specific interactions involving eIF3β within the complex or between eIF3 and other translation initiation factors. For instance, some inhibitors, such as Rocaglamide and Pateamine A, are known to disrupt the interaction between eIF3β and other initiation factors like eIF4A and eIF4G, thereby preventing the formation of essential translation initiation complexes like eIF4F. Others, like Ribavirin and Emetine, induce errors during translation, leading to ribosome stalling and inhibiting the translation process. Overall, eIF3β inhibitors represent a diverse class of compounds that function by perturbing the critical steps involved in translation initiation. Their specific mechanisms of action may vary, but their common objective is to disrupt the formation of translation initiation complexes, thereby modulating protein synthesis. This class of inhibitors provides valuable tools for researchers aiming to study the intricate regulatory mechanisms of protein synthesis and its implications for cellular physiology.